This review discusses the mechanisms of action of 4 immune modulating drugs currently
used in the treatment of multiple sclerosis (MS), including Alemtuzumab, a humanized …

The fundamental role of inflammatory immune processes in the pathology of multiple
sclerosis (MS) provides the rationale for immunomodulatory therapies that attempt to shift …

Several of the emerging therapies focusing on immune-mediated disease mechanisms
seem to offer stronger efficacy than the currently approved immune modulators for MS …

Multiple sclerosis (MS) is the most common disabling neurological disease of young
adulthood. Following advances in the understanding of the immunological mechanisms that …

We provide a focused review of novel immunomodulatory approaches for the treatment of
multiple sclerosis, the most common acquired inflammatory demyelinating disease of …

Highlights•Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord.•
Immunomodulatory drugs have been used for over two decades to treat relapsing MS.•Their …

Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized
by episodic and progressive neurological dysfunction resulting from inflammatory and …

In the last decade, a new armamentarium of immune-based therapies have been developed
and tested in patients with multiple sclerosis. Some of these therapies are showing a high …

Multiple sclerosis (MS) is a complex neurological disorder characterized by inflammation
and degeneration of the central nervous system, primarily involving the white matter. On the …

Multiple sclerosis is a chronic disease confined to the central nervous system. Its
pathological hallmarks are neuroinflammation, de-and re-myelination, neurodegeneration …